Argatroban
- Atc Codes:B01AE03
- CAS Codes:141396-28-3#74863-84-6
- PHARMGKB ID:141396-28-3#74863-84-6
Table of contents
- Brand Names
- Chemistry
- Pharmacologic Category
- Mechanism of Action
- Therapeutic Use
- Pregnancy and Lactation Implications
- Contraindications
- Warnings and Precautions
- Adverse Reactions
- Caution and personalized dose adjustment in patients with the following genotypes
- Other genes that may be involved
- Substrate of
- Drug Interactions
- Nutrition/Nutraceutical Interactions
- Dosage
- Pharmacokinetics and Pharmacodynamics
- Special Considerations
Brand Names
Europe
Austria: Argatra; Denmark: Novastan; Germany: Argatra; Greece: Argatroban; Italy: Novastan; Netherlands: Arganova; Sweden: Novastan.
North America
Canada: Argatroban; USA: Argatroban.
Asia
Japan: Argaron, Argatroban, Gartban, Novastan, Slonnon, Slovastan.
Drug combinations
Chemistry
Argatroban: C~23~H~36~N~6~O~5~S H~2~O. Mw: 526.65. (1) 2-Piperidinecarboxylic acid, 1-[5-[(aminoiminomethyl)amino]-1-oxo-2-[[(1,2,3,4-tetrahydro-3-methyl-8-quinolinyl)sulfonyl]amino]pentyl]-4-methyl-, monohydrate; (2)(2R,4R)-4-Methyl-1-[N^2^-[(1,2,3,4-tetrahydro-3-methyl-8-quinolyl)sulfonyl]-L-arginyl]pipecolic acid, monohydrate. CAS-141396-28-3; CAS-74863-84-6 (anhydrous)(1997).
Pharmacologic Category
Antithrombotic Agents; Anticoagulants; Direct Thrombin Inhibitors. (ATC-Code: B01AE03).
Mechanism of action
Reversibly binds to the active thrombin site of free and clot-associated thrombin. Inhibits fibrin formation, activation of coagulation factors V, VIII, and XIII, protein C, and platelet aggregation.
Therapeutic use
Prophylaxis or treatment of thrombosis with heparin-induced thrombocytopenia. Adjunct to percutaneous coronary intervention in patients who have or are at risk of thrombosis associated with heparin-induced thrombocytopenia.
Pregnancy and lactiation implications
Should be used during pregnancy only if clearly needed. Use not recommended during lactation.
Unlabeled use
Contraindications
Hypersensitivity to argatroban or any component of the formulation. Overt major bleeding.
Warnings and precautions
Bleeding is common. Use with caution in hepatic impairment or in critically-ill patients. Parenteral anticoagulants should be discontinued prior to initiating therapy. Concomitant use with warfarin will cause increased prolongation of the PT and INR.